Bleeding and thromboembolism risk of standard antithrombotic prophylaxis after hip or knee replacement within an enhanced recovery program

• Published in: Orthopaedics & traumatology, surgery & research surgery & research, 2020-12, Vol.106 (8), p.1533-1538
• Main Authors: Jenny, Jean-Yves, Bulaid, Yassine, Boisrenoult, Philippe, Bonin, Nicolas, Henky, Pierre, Tracol, Philippe, Chouteau, Julien, Courtin, Cyril, Henry, Marc-Pierre, Schwartz, Claude, Mertl, Patrice, De Ladoucette, Aymard
• Format: Article
• Language: English
• Subjects: Bleeding; Life Sciences; Prophylaxis; Total hip arthroplasty; Total knee arthroplasty; Venous thrombosis event
• ISSN: 1877-0568; 1877-0568
• DOI: 10.1016/j.otsr.2020.02.026

Prevention of venous thromboembolism (VTE) generally consists of low molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs) after total hip arthroplasty (THA) or total knee arthroplasty (TKA). Enhanced recovery after surgery (ERAS) protocols may reduce the VTE risk after these procedures. The aim of this study was to compare the risk of VTE and the risk of bleeding complications in a non-selected population of primary THA and TKA cases done within an ERAS protocol. The risk of postoperative VTE after primary THA and TKA is lower than the risk of bleeding complications within an ERAS protocol. This was a prospective observational study conducted on a national scale in France. All patients who underwent primary unilateral THA or TKA at one of 11 participating hospitals between October 2016 and October 2017 were enrolled and followed for 3 months. The occurrence of a VTE or major bleeding event was recorded. No patients were lost to follow-up at 3 months. Of the 1110 THA cases, there were 5 VTE (0.4%) and 19 bleeding events (1.7%). Of the 893 TKA cases, there were 9 VTE (1.0%) and 14 bleeding events (1.7%). There was no significant difference in the VTE incidence and bleeding event incidence after THA and TKA. The overall incidence of bleeding complications (1.7%) was significantly greater than the overall incidence of VTE complications (0.7%) (p=0.005). This was the case after THA (p=0.004) but not after TKA. The primary finding of this study is that bleeding complications are significantly more common than VTE complications after THA or TKA within an ERAS protocol. Based on these findings, the cost-benefit ratio of antithrombotic prophylaxis by LMWH or DOACs in this context should be reassessed. Level of evidence: IV; Prospective cohort study without control group.